2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
28
Neoplasms
13
Colonic Neoplasms
12
Breast Neoplasms
12
Prostatic Neoplasms
9
Polycythemia Vera
9
Venous Thromboembolism
8
Multiple Myeloma
8
Recurrence
6
Carcinoma, Non-Small-Cell Lung
6
Rectal Neoplasms
5
Thrombocythemia, Essential
4
Ovarian Neoplasms
4
Neoplasms, Plasma Cell
4
Neoplasm Metastasis
4
Myeloproliferative Disorders
4
Esophageal Neoplasms
4
Cardiovascular Diseases
4
Barrett Esophagus
4
Stomach Neoplasms
3
Precancerous Conditions
3
Melanoma
3
Lung Neoplasms
3
Gastrointestinal Neoplasms
3
Adenomatous Polyps
3
Adenoma
3
Tobacco Use Disorder
2
Thrombosis
2
Thromboembolism
2
Smoking Cessation
2
Interventions
dacetuzumab
2
Antineoplastic Agents
2
ficlatuzumab
1
Vorinostat
1
Vitamin E
1
Tinzaparin
1
Plastic Surgery Procedures
1
Lenalidomide
1
Erlotinib Hydrochloride
1
Dexamethasone
1
Calcium Dobesilate
1
Bortezomib
1
Blood Specimen Collection
1
Aspirin
1
ARQ531
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vascular Diseases
×
Aspirin
×
Clear all
NCT00000479
2012-06-15
WHS
Brigham and Women's Hospital
Phase 3
Completed
39,876 enrolled
11 charts